HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NVCR
NovoCure Limited
NVCR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NVCR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
NVCR's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NVCR PE Valuation
NVCR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NVCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
NVCR has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NVCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.55 |
| Q2 2026 | -$1.30 | +$0.26 |
| Q1 2026 | -$1.53 | -$0.02 |
| Q4 2025 | -$1.22 | +$0.34 |
| Q3 2025 | -$1.61 | -$0.21 |
| Q2 2025 | -$1.56 | +$0.02 |
| Q1 2025 | -$1.51 | +$0.30 |
| Q4 2024 | -$1.56 | +$0.39 |
NVCR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NVCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NVCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $193.4M | +16% |
| Q2 2026 | $183.6M | +16% |
| Q1 2026 | $174.1M | +12% |
| Q4 2025 | $174.4M | +8.1% |
| Q3 2025 | $167.2M | +7.8% |
| Q2 2025 | $158.8M | +5.6% |
| Q1 2025 | $155M | +12% |
| Q4 2024 | $161.3M | +21% |
NVCR's revenue has grown year over year for 12 quarters in a row: $193M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.2% | +18 points |
| Q2 2026 | -5.8% | +19 points |
| Q1 2026 | -39% | -14 points |
| Q4 2025 | -23% | +16 points |
| Q3 2025 | -22% | -0.8 points |
| Q2 2025 | -25% | -2.6 points |
| Q1 2025 | -24% | +5.6 points |
| Q4 2024 | -39% | -0.6 points |
NVCR has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NVCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
NVCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.7M | +5.5% |
| Q2 2026 | $1.2M | +$22.6M |
| Q1 2026 | -$18.7M | +$27.6M |
| Q4 2025 | -$22.9M | -$10.5M |
| Q3 2025 | $14.9M | +$15.2M |
| Q2 2025 | -$21.4M | -$8.3M |
| Q1 2025 | -$46.3M | -$2.9M |
| Q4 2024 | -$12.4M | +$9M |
NVCR's free cash flow was −$25M over the past year, against −$65M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NVCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NVCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +773K shares |
| 1 year | +4.4% | +4.9M shares |
| 3 years | +9.4% | +10M shares |
| 5 years | +13% | +13.1M shares |
| Available history | +8.2% | +8.9M shares |
NVCR has 117M diluted shares, up 4.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NVCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -105.8x | Net Cash |
| Q2 2021 | 8.7x | High |
| Q1 2021 | 5.7x | High |
| Q4 2020 | 4.9x | High |
| Q3 2020 | -8.5x | Net Cash |
| Q2 2020 | -2.9x | Net Cash |
| Q1 2020 | -3.2x | Net Cash |
| Q4 2019 | -3.7x | Net Cash |
NVCR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NVCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.6 | Neutral |
| Stochastic | 14.2 | Oversold |
NVCR's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NVCR PE vs Healthcare Sector
| Metric | NVCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NVCR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NVCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 16% below |
| 20 week MA | $15.6 | 25% below |
| 50 week MA | $14.5 | 19% below |
| 100 week MA | $16.0 | 27% below |
| 200 week MA | $23.3 | 50% below |
NVCR is in a downtrend: it's below all five of its weekly moving averages, and 50% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NVCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.6 | $172.0 | +96% |
| 2021 | $172.0 | $84.0 | -51% |
| 2022 | $84.0 | $73.0 | -13% |
| 2023 | $73.0 | $14.9 | -80% |
| 2024 | $14.9 | $30.7 | +106% |
| 2025 | $30.7 | $13.5 | -56% |
| 2026 YTD | $13.5 | $11.7 | -13% |
NVCR has the edge over HIMS on returns for 2026, with the stronger performance.